Pre-treatment risk factors to predict early cisplatin-related nephrotoxicity in locally advanced head and neck cancer patients treated with chemoradiation: A single Institution experience

Impact of acute kidney injury on overall survival in postoperative patients with head and neck cancer who received chemoradiotherapy with cisplatin: A supplementary analysis of a phase II/III trial of JCOG1008.

(2023) Yoshinori Imamura et al.   JOURNAL OF CLINICAL ONCOLOGY

Avasopasem manganese (GC4419) protects against cisplatin-induced chronic kidney disease: An exploratory analysis of renal metrics from a randomized phase 2b clinical trial in head and neck cancer patients

(2023) K.A. Mapuskar et al.   Redox Biology

Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial

(2022) Naomi Kiyota et al.   JOURNAL OF CLINICAL ONCOLOGY

Sex Difference in Cisplatin-Induced Nephrotoxicity: Laboratory and Clinical Findings

(2022) Fatemeh Eshraghi-Jazi et al.   Journal of Toxicology

914MO Standard versus fractionated high dose cisplatin concomitant with radiotherapy in locally advanced head & neck squamous cell cancer (LA-HNSCC): Results of the GORTEC 2015-02 CisFRad randomized trial

(2020) C. Borel et al.   ANNALS OF ONCOLOGY

Avelumab–cetuximab–radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH)

(2020) Yungan Tao et al.   EUROPEAN JOURNAL OF CANCER

Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin

(2019) Maurice J. D. L. van der Vorst et al.   BMC CANCER

Retrospective Analysis of Cisplatin Nephrotoxicity in Patients With Head and Neck Cancer Receiving Outpatient Treatment With Concurrent High-dose Cisplatin and Radiotherapy

(2018) Jennifer Faig et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Development and Validation of a Risk Prediction Model for Acute Kidney Injury After the First Course of Cisplatin

(2018) Shveta S. Motwani et al.   JOURNAL OF CLINICAL ONCOLOGY

A Systematic Review of Strategies to Prevent Cisplatin‐Induced Nephrotoxicity

(2017) Daniel J. Crona et al.   ONCOLOGIST

Weekly Low‐Dose Versus Three‐Weekly High‐Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non‐Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta‐Analysis of Aggregate Data

(2017) Petr Szturz et al.   ONCOLOGIST

Cisplatin Nephrotoxicity Might Have a Sex Difference. An analysis Based on Women's Sex Hormone Changes.

(2017) Wei-Yu Chen et al.   Journal of Cancer

Nephrotoxicity as a Dose-Limiting Factor in a High-Dose Cisplatin-Based Chemoradiotherapy Regimen for Head and Neck Carcinomas

(2016) Jantien Hoek et al.   Cancers

Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review

(2015) Primož Strojan et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Protective Effect of Magnesium Preloading on Cisplatin-induced Nephrotoxicity: A Retrospective Study

(2014) T. Yoshida et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Pathophysiology of Cisplatin-Induced Acute Kidney Injury

(2014) Abdullah Ozkok et al.   Biomed Research International

Incidence, Outcomes, and Comparisons across Definitions of AKI in Hospitalized Individuals

(2013) X. Zeng et al.   Clinical Journal of the American Society of Nephrology

Comparison of Acute Toxicities in Two Primary Chemoradiation Regimens in the Treatment of Advanced Head and Neck Squamous Cell Carcinoma

(2012) Katherine Y. Fan et al.   ANNALS OF SURGICAL ONCOLOGY